ADCT-602
2017-0938
Phase 2 mab terminated
Quick answer
ADCT-602 for Blasts 5 Percent or More of Bone Marrow Nucleated Cells is a Phase 2 program (mab) at ADC Therapeutics SA with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ADC Therapeutics SA
- Indication
- Blasts 5 Percent or More of Bone Marrow Nucleated Cells
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated